Lilly's $3.8 Billion Vaccine Bets: A Quiet Shift Now
Lilly's heavy reliance on GLP-1 drugs has investors watching as the company bets $3.8B on vaccines. This analysis exp...
Starting 401k contributions early can significantly boost your retirement savings. Aim to start as soon as you are eligible.
10,942 articlesLilly's heavy reliance on GLP-1 drugs has investors watching as the company bets $3.8B on vaccines. This analysis exp...
Healthcare fraud hits your wallet. This piece explains a real case where a lab owner allegedly billed Medicaid for te...
Wegovy continues to lead the U.S. GLP-1 market despite Eli Lilly's Foundayo launch. Investors are weighing uptake, pa...
Goldman Sachs reports a sub-1% acceptance rate for its 2026 summer internship—the third straight year of extreme sele...
When lululemon shares dropped after the company cut its annual forecast, it sent a clear message about the market's g...
Eli Lilly is shaking up its growth plan by expanding beyond obesity with new infectious disease initiatives. This art...
As market volatility rattles mid-year trading, a growing cohort of traders is turning to funded trading accounts. Thi...
As private markets steal the spotlight, Brookfield Asset Management and Ares Management stand out. This in-depth, ori...
Two very different apparel plays: FIGS targets a niche medical market with growth potential, while Gildan Activewear ...
Dive into Lakeland’s 2027 earnings narrative. Learn the drivers, margins, risks, and how to assess the stock for long...
Fidelity’s technology-focused ETF has sprinted ahead in 2026, delivering sizeable gains while the broad market stagna...
A trio of AI hardware leaders—Broadcom, AMD, and NVIDIA—fell in synchronized trading as investors weigh AI margins, m...